Udenafil 100 mg + Dapoxetine 60 mg combines a PDE5 inhibitor with a short‑acting SSRI to address coexisting erectile dysfunction and premature ejaculation in a single on‑demand dose, enhancing penile cGMP‑mediated vasodilation and delaying ejaculatory reflex via central serotonergic modulation. Pharmacokinetic data show no clinically significant interaction between udenafil and dapoxetine at high single doses, with coadministration generally well tolerated in healthy men. Clinical evidence supports adding on‑demand dapoxetine to a stable PDE5 regimen for meaningful improvements in intravaginal ejaculatory latency and patient‑reported outcomes when both conditions are present.